Evogene Ltd. ( EVGN) - Key Metrics
EVGN Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.03 | -$0.14 | -$0.17 | -$0.17 |
| 2026Q1 | $0.03 | -$0.60 | -$0.30 | -$0.30 |
| 2025Q4 | $0.04 | -$0.61 | -$0.31 | -$0.31 |
| 2025Q3 | $0.04 | $0.44 | -$0.43 | -$0.44 |
| 2025Q2 | $0.12 | -$0.62 | -$0.32 | -$0.32 |
EVGN Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | -144.09% | -0.78 |
| 2026Q1 | -3.29% | -0.32 |
| 2025Q4 | 0% | -0.45 |
| 2025Q3 | 0% | 0.65 |
| 2025Q2 | 0% | -0.52 |
EVGN Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q2 | -39.40% | 47.58% |
| 2026Q1 | -39.42% | 2.57% |
| 2025Q4 | -28.07% | 0% |
| 2025Q3 | -38.26% | 0% |
| 2025Q2 | -24.90% | 0% |
EVGN
Price: $0.48
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.75 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: Israel
Volume: 71621
Ebitda: -8.5 millionMarket Capitalization: 4.6 million